Copyright © 2023 InvestorsHub Inc.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GH—(-34%/AH)—reports_results_of “Shield” ctDNA—(liquid biopsy)—diagnostic_for colorectal cancer: https://finance.yahoo.com/news/guardant-health-announces-positive-results-211600504.html https://finance.yahoo.com/news/1-guardant-dna-blood-test-220041937.html GH’s data aren’t bad, but they aren’t as good as those for EXAS’s Cologuard, which is based on a stool sample rather than a blood sample. EXAS is +24%/AH, adding about $2B(!) to its market cap. In #msg-168735158 (from May 2022), I said:
Although GH says Shield is as good as EXAS’ Cologuard and MYNZ’s ColoAlert, I find it hard to believe that a blood test can be as sensitive for CRC (and precancerous lesions) as a stool-based test.
I'm still feeling very good about owning this stock. There is no way I'll sell this before the next five years.
I like the nice, gradual, consistent rise in the share price. I think there is no way to lose money here, and I think the gains will be very substantial over the next two to three years.
So am I. This is THE company I have chosen in which to put my investment dollars that I feel is both a high-growth situation and one in which I am certain not to lose money.
2-3 years I'm thinking this is @ 3-5X current share price
Register for free to join our community of investors and share your ideas
You'll also get access to streaming quotes, interactive charts, trades, portfolio, live options flow